Slide 1: Agilent Technologies Q4'21 Results Presentation
Agilent Technologies Q4’21 Results Presentation
Slide 2: Safe Harbor
Safe Harbor These presentations contain forward-looking statements (including, without limitation, information, and future guidance on the company’s goals, priorities, revenue, revenue growth, earnings per share, operating margin, operating cash flow, capital expenditures, capital allocation, growth
Slide 3: Agilent Results FY'21
Agilent Results FY'21 Fiscal year concludes with record performance on the top- and bottom-lines FY'21 Financial Metrics FY’21 Highlights • Revenues: $6.32B, +15.2% y/y • Growth was broad-based, with all markets and regions core(1)(2),+18.4% reported (2.9% FX, 0.3% growing at least mid-single digits
Slide 4: Results Q4'21
Agilent Results Q4'21 Scale and leading technology across Analytical Laboratories and Dx & Clinical markets Q4'21 Financial Metrics Q4’21 Highlights • Revenues: $1.66B, +10.7% y/y • Growth was driven by continued strength in Pharma and core(1)(2),+12.0% reported (0.8% FX, 0.5% BioPharma, while Chemi
Slide 5: Life Sciences & Applied Markets Group (LSAG)
Life Sciences & Applied Markets Group (LSAG) • Q4 core revenue performance reflected strength in Instrumentation and Informatics key end markets led by Pharma and Chemical & for Analytical Laboratories Energy. Momentum across all platforms led by LC, Cell Analysis, and Spectroscopy. • At the America
Slide 6: Cross Lab Group (ACG)
Agilent Cross Lab Group (ACG) Analytical Laboratory • ACG growth in Q4 was led by strong Consumables and Services consumables revenues across the portfolio, while both contract and on-demand services continued to deliver to high expectations despite difficult year- over-year compares. • Agilent sign
Slide 7: Diagnostics and Genomics Group (DGG)
Diagnostics and Genomics Group (DGG) • Q4 core revenue growth was led by another Pathology, Genomics, and outstanding performance in NASD and strong Nucleic Acid Manufacturing demand for genomics instrumentation. Cancer Dx also continued momentum developed across FY21. • Received FDA companion diagn
Slide 8: Growth in a $58B Market – Q4'21 Results by End Market
Growth in a $58B Market – Q4'21 Results by End Market Continued momentum in Pharma, C&E, and Dx & Clinical markets Analytical Laboratory End Markets Q4'21 revenues: +11% y/y on core(2) basis Pharma & Biotech: Up 21% on continued BioPharma strength in the US and China Chemical & Energy: Up 11%,
Slide 9: Q1'22 and FY22 Guidance and Forward-looking Considerations
Q1’22 and FY22 Guidance and Forward-looking Considerations Based on October 31, 2021 Exchange Rates Q1’22 Guidance (1) FY22 Guidance (1) Low End High End Low End High End Net Revenue ($M) $1,640 $1,660 Net Revenue ($M) $6,650 $6,730 Y/Y Core Revenue Growth (2) 5.9% 7.2% Y/Y Core Revenue Growth (2) 5